news flash·2025-04-30 09:36Core Viewpoint - Fudan Zhangjiang announced a price reduction of at least 35% for its Doxorubicin Liposome Injection starting from May 1, 2025, which is expected to negatively impact the company's sales revenue in 2025 and beyond [1] Group 1: Company Impact - The Doxorubicin Liposome Injection generated approximately RMB 210 million in sales revenue for the year 2024, accounting for 29% of the company's total annual sales revenue [1] - The price adjustment is anticipated to lead to a potential single-product loss for the Doxorubicin Liposome Injection in 2025 [1] Group 2: Market Implications - The decision to lower the price reflects the company's strategy to remain competitive in the market, but it poses risks to future revenue streams [1]